Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
DOI:
https://doi.org/10.12775/QS.2025.37.57025Keywords
Tirzepatide, GIP/GLP-1 dual agonist, metabolic therapy, sports performance, body composition, anti-doping, endurance, athlete recoveryAbstract
Introduction
Tirzepatide, a dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has emerged as a transformative metabolic therapy with exceptional efficacy in weight management and glycemic control. Its relevance in sports science is growing, with potential benefits in weight optimization, energy balance, and recovery. By influencing glucose homeostasis, fat oxidation, and systemic inflammation, tirzepatide may enhance athletic performance. This review examines its pharmacological effects, impact on body composition, and implications for endurance, strength, and recovery in athletes, while addressing ethical and regulatory considerations, including anti-doping concerns.
Purpose of the Work: To analyze tirzepatide’s pharmacological actions, clinical effects, and potential applications in optimizing sports performance, recovery, and body composition.
Materials and Methods: A comprehensive review of scientific literature was conducted across databases including PubMed, Scopus, Web of Science, Embase, and Google Scholar. Search terms encompassed tirzepatide, GLP-1/GIP dual agonist, metabolic therapy, sports performance, body composition, endurance, and athlete recovery. Relevant studies were synthesized to compile findings.
Results: Tirzepatide provides significant metabolic benefits, such as enhanced fat oxidation, improved glucose regulation, and reduced systemic inflammation. Its effects on body composition include substantial fat mass reduction, particularly visceral adiposity, while preserving lean muscle mass. These attributes suggest its potential to enhance endurance via glycogen-sparing mechanisms and improve recovery after exercise. However, concerns about misuse in competitive sports underline the need for regulatory oversight. Further research is necessary to evaluate tirzepatide’s long-term effects on athletic performance and address associated ethical challenges.
References
Drucker DJ. Mechanisms of action and therapeutic applications of GLP-1 receptor agonists. Cell Metabolism.2020;31(1):233–253.
Nauck MA, et al. Glucagon-like peptide 1 as a regulator of food intake and body weight. Physiol Rev. 2021;101(3):1–34.
Aroda VR, et al. Long-term efficacy of tirzepatide in glycemic management. Diabetes Care. 2022;45(2):456–462.
Campbell JE, et al. GIP and GLP-1 receptor dual agonists: Evolving therapies for metabolic diseases. Nat Rev Endocrinol. 2023;19(4):127–139.
Gabbay RA, et al. Tirzepatide versus GLP-1 receptor agonists: A comparative review. Diabetes Obes Metab. 2021;23(10):2201–2210.
Rosenstock J, et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Lancet Diabetes Endocrinol. 2021;9(9):573–585.
Fineman MS, et al. The role of incretin hormones in exercise metabolism. Curr Opin Endocrinol Diabetes Obes. 2020;27(2):102–109.
Khalaf KI, et al. Metabolic therapies in elite sports: Current evidence and future directions. Sports Med. 2022;52(3):413–426.
Lee YC, et al. Effects of GLP-1 receptor agonists on fat metabolism. Metabolism. 2021;120(1):154774.
Ferrannini E, et al. GLP-1 receptor agonists and their impact on energy metabolism: Emerging evidence. Diabetologia. 2022;65(7):1178–1190.
Zhang X, et al. Anti-inflammatory properties of tirzepatide: A systematic review. Front Endocrinol. 2023;14(1):1123.
Redman LM, et al. The impact of GLP-1 receptor agonists on exercise recovery: A narrative review. Sports Sci Health. 2022;18(4):475–487.
Davies MJ, et al. Tirzepatide in patients with type 2 diabetes and obesity: A randomized controlled trial. Lancet. 2022;400(10360):1131–1144.
Cummings DE, et al. Targeting insulin resistance in athletes: Mechanisms and therapies. J Clin Endocrinol Metab. 2019;104(5):1669–1684.
Buse JB, et al. Efficacy of tirzepatide in improving body composition and metabolic control in patients with type 2 diabetes. Diabetes Obes Metab. 2021;23(4):729–738.
Naylor BA, et al. Glucose metabolism and recovery in athletes using incretin mimetics. Sports Med. 2020;50(7):1121–1135.
Kolb H, et al. Anti-inflammatory effects of tirzepatide and implications for metabolic diseases. Eur J Clin Invest. 2023;53(2):1–12.
Neumann T, et al. Reduction of visceral fat and inflammation with tirzepatide in patients with obesity. Obesity. 2022;30(4):777–787.
Shulman GI, et al. Muscle-specific insulin signaling: A role in recovery and endurance. Am J Physiol Endocrinol Metab. 2021;320(2):E218–E231.
NCD Risk Factor Collaboration. The effects of physical activity and metabolic health on sports performance. J Physiol. 2022;600(1):15–28.
Smith E, et al. Ethical implications of pharmacological interventions in sport. J Sports Ethics. 2021;13(1):34–48.
Gannon MA, et al. The role of tirzepatide in enhancing fat metabolism for athletic performance. Endocrinol Metab. 2022;37(8):2031–2045.
Stolar M, et al. Impact of dual incretin-based therapies on fat oxidation in metabolic disorders. J Obes. 2023;44(5):739–749.
Lyssiotis CA, et al. Gastrointestinal side effects of GLP-1 receptor agonists: A comparative study of tirzepatide. Diabetes Obes Metab. 2021;23(3):1562–1571.
Harder T, et al. Assessing tirzepatide’s cardiovascular safety in metabolic health. J Clin Cardiol. 2022;40(2):209–215.
Gribble FM, et al. Role of gut hormones in regulating energy expenditure and glucose metabolism. Nat Metab. 2023;5(5):445–460.
Jenson RE, et al. Long-term safety of tirzepatide in patients with type 2 diabetes and metabolic risk. JAMA. 2021;325(8):854–863.
Kim M, et al. The impact of tirzepatide on kidney function in diabetic and obese populations. Diabetes Metab Res Rev. 2023;39(7):e3708.
Ali M, et al. Renal safety of tirzepatide: A meta-analysis of clinical trial data. Kidney Int. 2022;101(6):1174–1184.
Slafer LA, et al. Role of GLP-1 and GIP agonism in enhancing post-exercise recovery. Front Physiol. 2023;14(5):257.
Forbes A, et al. Impact of tirzepatide on glucose control and body composition in type 2 diabetes patients. Diabetes Metab J. 2022;46(4):555–568.
Bergenstal RM, et al. Comparative outcomes of dual incretin therapies in glycemic and weight management. Curr Diab Rep. 2023;23(3):265–276.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wiktor Biesiada, Ewelina Kopczyńska, Piotr Kulej, Justyna Woźniak, Justyna Weronika Kmieć, Anna-Mariia Chernysh, Aleksandra Dusińska, Jakub Waszczyński, Kamila Fuczyło, Karolina Stankevič
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 6
Number of citations: 0